Mild Cognitive Impairment
Diagnostic and Therapeutic Issues

“Experts in the field say a condition known as mild cognitive impairment (MCI), which precedes development of AD and other dementias in many people, appears to be a signal of disease onset that will help target individuals for early interventions.”

October 1-2, 1999
The Ritz-Carlton, St. Louis
St. Louis, Missouri

2nd Leonard Berg Symposium on Alzheimer’s Disease

Washington University School of Medicine
Dear Colleague:

Please accept my personal invitation to attend the 2nd Leonard Berg Symposium on Alzheimer’s Disease. This year’s program is entitled Mild Cognitive Impairment: Diagnostic and Therapeutic Issues and complements the mild cognitive impairment (MCI) meeting held earlier this year as reported in JAMA (1999;282[7]:621-622). This invaluable program will examine MCI, covering topics such as diagnostic issues, clinical course, neuroimaging, and treatment. This program is made possible through an unrestricted educational grant from the U.S. Pharmaceuticals Group, Pfizer Inc, and Eisai Inc. and is sponsored by the Alzheimer’s Disease Research Center of Washington University School of Medicine.

The meeting will be held October 1-2, 1999, in Clayton (near St. Louis), Missouri, at The Ritz-Carlton, St. Louis. To register for this program, please return the attached business reply card or call 1-800-835-7633. Seating is limited; please register as soon as possible.

I look forward to sharing this information with you and obtaining your feedback on the issues presented.

Respectfully,

John C. Morris, MD
Program Chairman

Faculty

John C. Morris, MD
Chairman
Harvey A. and Dorisame Hacker Friedman
Professor of Neurology
Washington University School of Medicine
Department of Neurology
St. Louis, Missouri

Marilyn S. Albert, PhD
Professor of Psychiatry
Director of Neurology
Harvard Medical School
Boston, Massachusetts

Steven T. DeKosky, MD
Professor of Psychiatry, Neurology,
and Neurobiology
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

David Knopman, MD
Professor, Associate Head
Department of Neurology
University of Minnesota Medical School
Minneapolis, Minnesota

Ronald C. Petersen, MD, PhD
Professor of Neurology
Mayo Clinic and Foundation
Rochester, Minnesota

Eric Reiman, MD
Professor and Associate Head of Psychiatry
University of Arizona
Tucson, Arizona

Martin Rossor, MA, MD, FRCP
Dementia Research Group
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

Peter Seubert, MD
Elan Pharmaceuticals
South San Francisco, California

Martha Storandt, PhD
Department of Psychology
Washington University
St. Louis, Missouri

Leon J. Thal, MD
Florence Riford Chair in Alzheimer’s Disease
Professor of Neurosciences
University of California
San Diego, California
Agenda

Friday, October 1, 1999

8:30 AM  Opening Remarks
John C. Morris, MD

SESSION I
Mild Cognitive Impairment: Relationship to Aging and Incipient Alzheimer's Disease (AD)

9:00  Characterization of Mild Cognitive Impairment (MCI)
Ronald C. Petersen, MD, PhD

9:30  Question and Answer Session

9:40  Cognitive Function in Nondemented Aging
Martha Storandt, PhD

10:10  Question and Answer Session

10:20  Break

10:40  Incipient AD: Clinical Detection
John C. Morris, MD

11:10  Question and Answer Session

11:20  Panel Discussion

11:50  Lunch

SESSION II
Are We Ready To Treat MCI?

12:50 PM  Trial Designs and Therapeutic Agents for MCI
Leon J. Thal, MD

1:20  Question and Answer Session

1:30  Cholinesterase Inhibitors in MCI
Steven T. DeKosky, MD

2:00  Question and Answer Session

2:10  Break

2:30  Antiamyloid Therapeutic Strategies
Peter Seubert, MD

3:00  Question and Answer Session

3:10  Are We Ready To Treat MCI?
A Clinical Perspective
David Knopman, MD

3:40  Question and Answer Session

3:50  Panel Discussion/Consensus Statement

4:20  Reception

Saturday, October 2, 1999

SESSION III
Neuroimaging in MCI

9:30 AM  Structural Neuroimaging and Cognitive Measures in Individuals at Risk for Familial AD
Martin Rossor, MA, MD, FRCP

10:00  Question and Answer Session

10:10  Assessing AD in the Absence of Symptoms Using Functional Neuroimaging
Eric Reiman, MD

10:40  Question and Answer Session

10:50  Break

11:10  Relating Neuroimaging to Neuropsychological Function in the Detection of Incipient AD
Marilyn S. Albert, PhD

11:40  Question and Answer Session

11:50  Panel Discussion

12:20 PM  Closing Remarks
John C. Morris, MD

12:30  Adjourn